» Articles » PMID: 23315496

Effect of the Purinergic Inhibitor Oxidized ATP in a Model of Islet Allograft Rejection

Abstract

The lymphocytic ionotropic purinergic P2X receptors (P2X1R-P2X7R, or P2XRs) sense ATP released during cell damage-activation, thus regulating T-cell activation. We aim to define the role of P2XRs during islet allograft rejection and to establish a novel anti-P2XRs strategy to achieve long-term islet allograft function. Our data demonstrate that P2X1R and P2X7R are induced in islet allograft-infiltrating cells, that only P2X7R is increasingly expressed during alloimmune response, and that P2X1R is augmented in both allogeneic and syngeneic transplantation. In vivo short-term P2X7R targeting (using periodate-oxidized ATP [oATP]) delays islet allograft rejection, reduces the frequency of Th1/Th17 cells, and induces hyporesponsiveness toward donor antigens. oATP-treated mice displayed preserved islet grafts with reduced Th1 transcripts. P2X7R targeting and rapamycin synergized in inducing long-term islet function in 80% of transplanted mice and resulted in reshaping of the recipient immune system. In vitro P2X7R targeting using oATP reduced T-cell activation and diminished Th1/Th17 cytokine production. Peripheral blood mononuclear cells obtained from long-term islet-transplanted patients showed an increased percentage of P2X7R⁺CD4⁺ T cells compared with controls. The beneficial effects of oATP treatment revealed a role for the purinergic system in islet allograft rejection, and the targeting of P2X7R is a novel strategy to induce long-term islet allograft function.

Citing Articles

Diabetes current and future translatable therapies.

Gonzalez-Sanchez F, Sanchez-Huerta T, Huerta-Gonzalez A, Sepulveda-Villegas M, Altamirano J, Aguilar-Aleman J Endocrine. 2024; 86(3):865-881.

PMID: 38971945 DOI: 10.1007/s12020-024-03944-8.


Sterile inflammation in liver transplantation.

Kahan R, Cray P, Abraham N, Gao Q, Hartwig M, Pollara J Front Med (Lausanne). 2023; 10:1223224.

PMID: 37636574 PMC: 10449546. DOI: 10.3389/fmed.2023.1223224.


Reversal of Experimental Autoimmune Diabetes With an sCD39/Anti-CD3 Treatment.

Fotino C, Molano R, Ben Nasr M, Umland O, Fraker C, Ulissi U Diabetes. 2023; 72(11):1641-1651.

PMID: 37625134 PMC: 10588287. DOI: 10.2337/db23-0178.


P2-type purinergic signaling in the regulation of pancreatic β-cell functional plasticity as a promising novel therapeutic approach for the treatment of type 2 diabetes?.

Mesto N, Movassat J, Tourrel-Cuzin C Front Endocrinol (Lausanne). 2023; 13:1099152.

PMID: 37065173 PMC: 10099247. DOI: 10.3389/fendo.2022.1099152.


P2 Receptors: Novel Disease Markers and Metabolic Checkpoints in Immune Cells.

Vultaggio-Poma V, Di Virgilio F Biomolecules. 2022; 12(7).

PMID: 35883539 PMC: 9313346. DOI: 10.3390/biom12070983.


References
1.
Arulkumaran N, Unwin R, Wk Tam F . A potential therapeutic role for P2X7 receptor (P2X7R) antagonists in the treatment of inflammatory diseases. Expert Opin Investig Drugs. 2011; 20(7):897-915. PMC: 3114873. DOI: 10.1517/13543784.2011.578068. View

2.
Makhlouf L, Kishimoto K, Smith R, Abdi R, Koulmanda M, Winn H . The role of autoimmunity in islet allograft destruction: major histocompatibility complex class II matching is necessary for autoimmune destruction of allogeneic islet transplants after T-cell costimulatory blockade. Diabetes. 2002; 51(11):3202-10. DOI: 10.2337/diabetes.51.11.3202. View

3.
Bloomgarden Z . Consequences of diabetes: cardiovascular disease. Diabetes Care. 2004; 27(7):1825-31. DOI: 10.2337/diacare.27.7.1825. View

4.
Rizzo R, Ferrari D, Melchiorri L, Stignani M, Gulinelli S, Baricordi O . Extracellular ATP acting at the P2X7 receptor inhibits secretion of soluble HLA-G from human monocytes. J Immunol. 2009; 183(7):4302-11. DOI: 10.4049/jimmunol.0804265. View

5.
Elliott M, Chekeni F, Trampont P, Lazarowski E, Kadl A, Walk S . Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature. 2009; 461(7261):282-6. PMC: 2851546. DOI: 10.1038/nature08296. View